(Q41056748)

26 September 2017

Prognostic relevance of lactate dehydrogenase and serum S100 levels in stage IV melanoma with known BRAF mutation status (English)

1 reference

26 September 2017

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26659191%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

author name string

A L Frauchiger

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26659191%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

J Mangana

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26659191%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

M Rechsteiner

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26659191%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

H Moch

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26659191%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

B Seifert

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26659191%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

R Dummer

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26659191%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

S M Goldinger

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26659191%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

language of work or name

English

0 references

publication date

13 December 2015

1 reference

British Journal of Dermatology

26 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26659191%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

volume

174

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26659191%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26659191%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

page(s)

823-830

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26659191%20AND%20SRC:MED&resulttype=core&format=json

Targeting the RAF-MEK-ERK pathway in cancer therapy

9 June 2020

cites work

1 reference

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

NRAS mutation status is an independent prognostic factor in metastatic melanoma

21 January 2018

1 reference

Clinical significance of BRAF mutations in metastatic melanoma

21 January 2018

1 reference

Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis

21 January 2018

1 reference

Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma

21 January 2018

1 reference

NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.

21 January 2018

1 reference

BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site

21 January 2018

1 reference

Determinants of BRAF mutations in primary melanomas

21 January 2018

1 reference

Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.

21 January 2018

1 reference

Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma.

21 January 2018

1 reference

Clinical correlates of NRAS and BRAF mutations in primary human melanoma

21 January 2018

1 reference

Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.

21 January 2018

1 reference

Prognostic factors for survival of patients treated systemically for disseminated melanoma.

21 January 2018

1 reference

Final version of 2009 AJCC melanoma staging and classification

21 January 2018

1 reference

Serum S100--a marker for disease monitoring in metastatic melanoma

21 January 2018

1 reference

Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis

21 January 2018

1 reference

Normal values of serum S-100B predict prolonged survival for stage IV melanoma patients

21 January 2018

1 reference

KRAS, BRAF, and TP53 deep sequencing for colorectal carcinoma patient diagnostics

21 January 2018

1 reference

The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.

21 January 2018

1 reference

The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis

21 January 2018

1 reference

BRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapy

21 January 2018

1 reference

Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma.

21 January 2018

1 reference

B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis

21 January 2018

1 reference

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

21 January 2018

1 reference

Serum S100B, lactate dehydrogenase and brain metastasis are prognostic factors in patients with distant melanoma metastasis and systemic therapy

21 January 2018

1 reference

S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles

21 January 2018

1 reference

The role of BRAF mutation and p53 inactivation during transformation of a subpopulation of primary human melanocytes

21 January 2018

1 reference

The luminescence immunoassay S-100: a sensitive test to measure circulating S-100B: its prognostic value in malignant melanoma

21 January 2018

1 reference

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

21 January 2018

1 reference

Improved survival with MEK inhibition in BRAF-mutated melanoma

21 January 2018

1 reference

NRAS and BRAF Mutations in Cutaneous Melanoma and the Association with MC1R Genotype: Findings from Spanish and Austrian Populations

21 January 2018

1 reference

Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/BJD.14347

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26659191%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

1 reference